Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cowen upgrades Regeneron to Outperform on Eylea success

Published 31/01/2023, 12:52 am
Updated 31/01/2023, 12:52 am
© Reuters.

© Reuters.

By Senad Karaahmetovic 

Cowen analysts upgraded Regeneron (NASDAQ:REGN) to Outperform from Market Perform and hiked the price target to $875 per share from the prior $775 as the company's pipeline is delivering solid results.

The analysts are especially encouraged by the success of the HD Eylea - the firm's macular degeneration franchise - which has managed to alter the trajectory of Regeneron, they wrote in a client note.

"With the future of the Eylea franchise re-secured, and Dupixent being a top growth asset in biopharma, REGN is likely to remain one of the more fundamentally attractive companies in LC biotech," the analysts wrote.

Hence, the raised rating and price target reflect increased out-year estimates for Eylea.

"The bottom line is that [Roche's] Vabysmo is not doing enough to offset the absolute market growth an asset the size of Eylea (~$10B) is generating (+11-14% Y/Y US in Q2-Q3 despite Vabysmo), and with a potential late August approval of HD Eylea, the window of opportunity is closing quickly. Additionally, with the Eylea > HD Eylea transition likely to occur rapidly, the impact of biosimilars will be minimal and out-year consensus estimates are too low," the analysts added.

Regeneron stock price closed at $742.83 on Friday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.